SEC Comment Letter for IGC Pharma, Inc. (IGC) (CIK 0001326205) (IGC) — Feb 5, 2009

IGC Pharma, Inc. (IGC) (CIK 0001326205)
Date: Feb. 5, 2009 · CIK: 0001326205 · Accession: 0000000000-09-006163

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

Date

February 5, 2009

Author

Jeffrey Gordon

Form

UPLOAD

Company

IGC Pharma, Inc. (IGC) (CIK 0001326205)

Letter

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549-7010 DIVISION OF CORPORATION FINANCE Mail Stop 7010 February 5, 2009 Mr. Ram Mukunda President and CEO India Globalization Capital, Inc. 4336 Montgomery Ave. Bethesda, MD 20814 RE: Form 8-K Item 4.01 filed May 8, 2008 Form 8-K/A Item 4.01 filed May 22, 2008 File #1-32830

Dear Mr. Mukunda: We have completed our review of your Fo rm 8-K and related filings and have no further comments at this time. If you have any further questions regard ing our review of your filings, please direct them to the undersigned at (202) 551-3866. S i n c e r e l y , Jeffrey Gordon S t a f f A c c o u n t a n t

Show Raw Text

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549-7010

       DIVISION OF
CORPORATION FINANCE

Mail Stop 7010
February 5, 2009
 Mr. Ram Mukunda President and CEO India Globalization Capital, Inc. 4336 Montgomery Ave. Bethesda, MD 20814  RE:   Form 8-K Item 4.01 filed May 8, 2008
 Form 8-K/A Item 4.01 filed May 22, 2008
 File #1-32830

Dear Mr. Mukunda:
We have completed our review of your Fo rm 8-K and related filings and have no
further comments at this time.
If you have any further questions regard ing our review of your filings, please
direct them to the undersigned at (202) 551-3866.           S i n c e r e l y ,             Jeffrey Gordon         S t a f f  A c c o u n t a n t

SecProbe.io